An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy

References

• GarmanSCGarbocziDNThe molecular defect leading to Fabry disease: structure of human alpha-galactosidaseJ Mol Biol2004337231933515003450
   PubMed Web of Science ®Google Scholar
• GermainDPFabry diseaseOrphanet J Rare Dis201053021092187
   PubMed Web of Science ®Google Scholar
• SchiffmannRKoppJBAustinHA3rdEnzyme replacement therapy in Fabry disease: a randomized controlled trialJAMA2001285212743274911386930
   PubMed Web of Science ®Google Scholar
• AertsJMGroenerJEKuiperSElevated globotriaosylsphingosine is a hallmark of Fabry diseaseProc Natl Acad Sci U S A200810582812281718287059
   PubMed Web of Science ®Google Scholar
• DesnickRJIoannouYAEngCMα-Galactosidase A deficiency: Fabry diseaseScriverCRBeaudetALSlyWSValleDThe Metabolic and Molecular Basis of Inherited Disease8th edNew YorkMcGraw-Hill200137333774
   Google Scholar
• WangRYLelisAMirochaJWilcoxWRHeterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of lifeGenet Med200791344517224688
   PubMed Web of Science ®Google Scholar
• WilcoxWROliveiraJPHopkinRJFemales with Fabry disease frequently have major organ involvement: lessons from the Fabry RegistryMol Genet Metab200893211212818037317
   PubMed Web of Science ®Google Scholar
• DeeganPBBaehnerAFBarba RomeroMAHughesDAKampmannCBeckMEuropean FOS InvestigatorsNatural history of Fabry disease in females in the Fabry Outcome SurveyJ Med Genet200643434735216227523
   PubMed Web of Science ®Google Scholar
• MacDermotKDHolmesAMinersAHNatural history of Fabry disease in affected males and obligate carrier femalesJ Inherit Metab Dis2001241314 discussion 11–1211758673
   PubMed Web of Science ®Google Scholar
• SestitoSCeravoloFConcolinoDAnderson-Fabry disease in childrenCurr Pharm Des201319336037604523448455
   PubMed Web of Science ®Google Scholar
• RiesMGuptaSMooreDFPediatric Fabry diseasePediatrics20051153e344e35515713906
   PubMed Web of Science ®Google Scholar
• RamaswamiUWhybraCPariniRClinical manifestations of Fabry disease in children: data from the Fabry Outcome SurveyActa Paediatr2006951869216498740
   PubMed Web of Science ®Google Scholar
• KampmannCWiethoffCMWhybraCBaehnerFAMengelEBeckMCardiac manifestations of Anderson-Fabry disease in children and adolescentsActa Paediatr200897446346918363956
   PubMed Web of Science ®Google Scholar
• RamaswamiUWendtSPintos-MorellGEnzyme replacement therapy with agalsidase alfa in children with Fabry diseaseActa Paediatr200796112212717187618
   PubMed Web of Science ®Google Scholar
• SchiffmannRMartinRAReimschiselTFour-year prospective clinical trial of agalsidase alfa in children with Fabry diseaseJ Pediatr20101565832837e83120097359
   PubMed Web of Science ®Google Scholar
• RiesMClarkeJTWhybraCEnzyme-replacement therapy with agalsidase alfa in children with Fabry diseasePediatrics2006118392493216950982
   PubMed Web of Science ®Google Scholar
• SchiffmannRPastoresGMLienYHAgalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up studyOrphanet J Rare Dis20149116925425121
   PubMedGoogle Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human UseICH Harmonised Tripartite Guideline: Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process2004 Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdfAccessed March 15, 2016
   Google Scholar
• European Medicines AgencyReplagal, agalsidase alfa2015 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000369/human_med_001029.jsp&mid=WC0b01ac058001d124Accessed February 22, 2016
   Google Scholar
• World Health OrganizationGrowth reference data for 5–19 years2007 Available from: http://www.who.int/growthref/en/Accessed January 8, 2014
   Google Scholar
• MassinMvon BernuthGNormal ranges of heart rate variability during infancy and childhoodPediatr Cardiol19971842973029175528
   PubMed Web of Science ®Google Scholar
• LangRMBierigMDevereuxRBRecommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of CardiologyJ Am Soc Echocardiogr200518121440146316376782
   PubMed Web of Science ®Google Scholar
• National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and AdolescentsThe fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescentsPediatrics20041142 Suppl 4th Report55557615286277
   PubMed Web of Science ®Google Scholar
• KampmannCLinhartABaehnerFOnset and progression of the Anderson-Fabry disease related cardiomyopathyInt J Cardiol2008130336737318572264
   PubMed Web of Science ®Google Scholar
• CharlesSCleelandThe Brief Pain Inventory User Guide1991 Available from: http://www.mdanderson.org/education-and-research/departments-programs-and-labs/departments-and-divisions/symptom-research/symptom-assessment-tools/BPI_UserGuide.pdfAccessed October 14, 2014
   Google Scholar
• FurlongWJFeenyDHTorranceGWHealth Utilities IncSelf-Complete Questionnaire Manual2012 Available from: http://www.healthutilities.com/manual.htmAccessed October 14, 2014
   Google Scholar
• HealthactchqCHQ: Child Health Questionnaire™2014 Available from: https://www.healthactchq.com/chq.phpAccessed October 14, 2014
   Google Scholar
• CrepazRCeminRPedronCGentiliLTrevisanDPitscheiderWAge-related variations of left ventricular endocardial and midwall function in healthy infants, children, and adolescentsItal Heart J20056863463916161496
   PubMedGoogle Scholar
• MorrisseyRPPhilipKJSchwarzERCardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathyCardiovasc J Afr2011221384421298206
   PubMed Web of Science ®Google Scholar
• KleigerREMillerJPBiggerJTJrMossAJDecreased heart rate variability and its association with increased mortality after acute myocardial infarctionAm J Cardiol19875942562623812275
   PubMed Web of Science ®Google Scholar
• ZuanettiGNeilsonJMLatiniRSantoroEMaggioniAPEwingDJPrognostic significance of heart rate variability in post-myocardial infarction patients in the fibrinolytic era. The GISSI-2 results. Gruppo Italiano per lo Studio della Sopravvivenza nell’ Infarto MiocardicoCirculation19969434324368759085
   PubMed Web of Science ®Google Scholar
• MehtaAWestMLPintos-MorellGTherapeutic goals in the treatment of Fabry diseaseGenet Med2010121171372020975569
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation IKDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease2007 Available from: http://www2.kidney.org/professionals/KDOQI/guideline_diabetes/guide1.htmAccessed September 30, 2015
   Google Scholar